MORGAN STANLEY PLC/CALL/STRYKER CORP./280/0.1/21.06.24 Share Price

Warrant

DE000MD9T581

Delayed Börse Stuttgart 09:14:44 17/06/2024 BST
6.02 EUR +1.35% Intraday chart for MORGAN STANLEY PLC/CALL/STRYKER CORP./280/0.1/21.06.24
Current month+6.64%
1 month+37.18%
Date Price Change
17/06/24 6.02 +1.35%
14/06/24 5.94 -0.67%
13/06/24 5.98 -2.92%
12/06/24 6.16 -1.12%
11/06/24 6.23 -1.27%

Delayed Quote Börse Stuttgart

Last update June 17, 2024 at 09:14 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying STRYKER CORPORATION
Issuer Morgan Stanley
WKN MD9T58
ISINDE000MD9T581
Date issued 26/10/2022
Strike 280 $
Maturity 21/06/2024 (4 Days)
Parity 10 : 1
Emission price 2.36
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 7.75
Lowest since issue 1.45

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
345 USD
Average target price
372.5 USD
Spread / Average Target
+7.98%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW